Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
New research presented at this year's annual meeting of the European Association for the Study of Diabetes (EASD) in Barcelona, Spain, shows that patients receiving sulfonylureas as first line treatment for type 2 diabetes have higher mortality than those receiving metformin. The researchers, led by Professor Craig Currie, Cardiff University, UK, say that it may no longer be appropriate to offer first line treatment with sulfonylureas as a result of these findings.
Sulfonylureas such as glipizide, gliclazide or glibenclamide are commonly prescribed as first line therapy in developed countries; for example 7% of people with type 2 diabetes in the UK. This class of drugs was first available in the 1950s. Metformin continues to be one of most commonlyt prescribed antidiabetes treatments, and also has been in use since the 1950s. In this study, Professor Currie and colleaguesevaluated the comparative risk of all-cause mortality for patients exposed to first-line diabetes monotherapy with either sulfonylureas or metformin.
The researchers extracted data from the retrospective data were extracted from the Clinical Practice Research Datalink (CPRD): a data resource comprising approximately 10% of all patients treated in primary care in the United Kingdom. Patients with type 2 diabetes initiated with first-line, glucose-lowering treatments between 2000 and 2012 were selected. The primary endpoint was all-cause mortality.
The authors performed a matched-cohort study comparing those treated with sulfonylureas (exposed) versus metformin (non-exposed) using the following matching criteria at baseline: age (±2 years), gender, year of index exposure, diabetes duration (±1 year), BMI (±3 kg/m2), serum creatinine (±10 μmol/l) and Hba1c (±1%).
The analysis showed that 76,811 patients were prescribed metformin monotherapy (mean follow-up 3 years), and 15,687 sulfonylureas (mean follow-up 3 years). Using two alternative methods of investigating possible study biases, 2,048 patients were included in each arm of the direct matched cohorts and 8,836 in the propensity matched. The data showed that patients prescribed sulfonylureas were 58% more likely to die from any cause than those prescribed metformin.
Professor Currie concludes: "Mortality was significantly increased in patients prescribed sulfonylureas as first-line, glucose lowering monotherapy, compared with metformin monotherapy. Whilst residual confounding and confounding by indication may remain, this study indicates that treatment with first-line monotherapy with sulfonylureas should be reconsidered."
Regarding why sulfonylureas might be prescribed as first-line therapy instead of metformin in the first place, Professor Currie concludes: ""Not all general practitioners or other doctors are fully informed about the risks and benefits of commonly used drugs. Failure to identify the higher mortality associated with certain drugs could also be regarded as a failure of the regulatory system."
European Association for the Study of Diabetes (EASD)
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Diabetes category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
EASD. "Mortality increased by 58% when sulfonylureas used as first-line therapy for type 2 diabetes instead of metformin." Medical News Today. MediLexicon, Intl., 27 Sep. 2013. Web.
4 Dec. 2013. <http://www.medicalnewstoday.com/releases/266667>
EASD. (2013, September 27). "Mortality increased by 58% when sulfonylureas used as first-line therapy for type 2 diabetes instead of metformin." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact the our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/266667.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2013 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.